|13th November 2020||Joel Lewis||6,061||Grant/award etc.||$2.75||$16,667.75|
|30th October 2020||Joel Lewis||6,562||Grant/award etc.||$2.54||$16,667.48|
|15th October 2020||Joel Lewis||5,807||Grant/award etc.||$2.87||$16,666.09|
|13th October 2020||Fund, L.P. 10 X||10,000||Open or private sale||$2.97||$29,700.00|
|30th September 2020||Joel Lewis||6,242||Grant/award etc.||$2.67||$16,666.14|
|29th September 2020||Gilbert S Omenn||20,000||Open or private purchase||$5.00||$100,000.00|
|15th September 2020||Joel Lewis||5,171||Grant/award etc.||$2.93||$15,151.03|
|4th September 2020||Kevin D Freeman||5,000||Open or private purchase||$2.57||$12,848.00|
|4th September 2020||Richard E Uihlein||10,000||Open or private purchase||$2.55||$25,500.00|
|19th March 2020||Kevin D Freeman||6,000||Open or private purchase||$1.64||$9,844.20|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Galectin Therapeutics, Inc. engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.